U-ACHIEVE

A Study to Evaluate the Long-Term Safety and Efficacy of an Active Drug in Subjects With Ulcerative Colitis (UC)

Brief summary

This study is designed to evaluate the long-term safety and efficacy of an active drug in participants with ulcerative colitis (UC) who have not responded at the end of the induction period in Study M14-234 Substudy 1, who have had loss of response during the maintenance period of Study M14-234 Substudy 3, or who have successfully completed Study M14-234 Substudy 3.

Interventional

Interventional study

Status:
Active, not recruiting
Conditions:
Ulcerative Colitis (UC)
Enrollment:
950 patients
Phase:
  • 1
  • 2
  • 3
  • 4
Protocol ID:
M14-533
Allocation:
Non-Randomized
Intervention model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Purpose:
Treatment

 

Eligibility criteria

Participant attributes:
Male and Female

Age:

From 16 Years to 75 Years.

Inclusion Criteria:

Note: Participants aged 16 or 17 may enroll in M14-234 or M14-675 where locally
permissible

- Participant has not achieved clinical response at the end of the induction period
(Week 8) in Study M14-234 Substudy 1, has had loss of response during the
maintenance period of Study M14-234 Substudy 3, or has successfully completed Study
M14-234 Substudy 3. During the COVID-19 pandemic, for participants with missing
endoscopy at Week 8, Week 16 or Week 52 due to the COVID-19 pandemic in Studies
M14-234 Substudy 2, M14-234 Substudy 3 and M14-675, participants may be enrolled if
certain criteria are met.

- If female, participant must meet the contraception criteria.

- Women of childbearing potential must have a negative urine pregnancy test at Week 0
visit.

- Participant is judged to be in otherwise good health as determined by the principal
investigator based upon clinical evaluations performed during the preceding study
(Study M14-234).

- Must be able and willing to give written informed consent and to comply with the
requirements of this study protocol.

Exclusion Criteria:

- For any reason participant is considered by the investigator to be an unsuitable
candidate.

- Female participant with a positive pregnancy test at the final visit of Study
M14-234 or who is considering becoming pregnant during the study or within 30 days
after the last dose of study drug.

- Known hypersensitivity to upadacitinib or its excipients or had any adverse event
(AE) during the preceding studies, that in the investigator's judgment makes the
participant unsuitable for this study.

- Participant with an active or recurrent infection that based on the investigator's
clinical assessment makes the participant an unsuitable candidate for the study.
Participants with ongoing infections undergoing treatment may be enrolled BUT NOT
dosed until the infection has been successfully treated.

- Current evidence of active tuberculosis (TB); current evidence of latent
tuberculosis and for any reason the participant cannot take full course of TB
prophylaxis treatment as required per protocol.

- Participant with a poorly controlled medical condition, such as uncontrolled
diabetes, unstable ischemic heart disease, moderate or severe congestive heart
failure (New York Heart Association class III or IV), recent cerebrovascular
accidents and any other condition which, in the opinion of the investigator or
sponsor, would put the subject at risk by participation in this study.

- Participants have malignancy, high-grade dysplasia, un-removed low-grade dysplasia
of the gastrointestinal tract diagnosed at the endoscopy performed at the final
visit of Study M14-234.

- History of any malignancy except for successfully treated nonmelanoma skin cancer
(NMSC) or localized carcinoma in situ of the cervix from evaluations performed in
Study M14-234.

All the cities where the clinical studies are located

Sherbrooke - J1G 2E8

More information about this study

clinicaltrials.gov